Why Fulgent Genetics, Inc.’s (FLGT) Stock Is Up 5.01%
As of Wednesday, August 19, Fulgent Genetics, Inc.’s FLGT share price has surged by 5.01%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. FLGT
$19.74
1.17
6.30%
August 19, 2026 4:00:00 PM
EST
Volume: 264,961
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Commentary & Analysis
Is Fulgent Genetics, Inc. (FLGT) Overvalued?
We dive into why Fulgent Genetics, Inc. (FLGT) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
Why Fulgent Genetics, Inc.’s (FLGT) Stock Is Up 5.44%
As of Monday, August 03, Fulgent Genetics, Inc.’s FLGT share price has surged by 5.44%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Fulgent Genetics, Inc.’s (FLGT) Stock Is Down 18.21%
As of Friday, July 31, Fulgent Genetics, Inc.’s FLGT share price has dipped by 18.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Fulgent Genetics, Inc.’s (FLGT) Stock Is Down 14.87%
As of Friday, July 31, Fulgent Genetics, Inc.’s FLGT share price has dipped by 14.87%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | FLGT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $547.3 | $1,982.5 | 38% |
|
| Shares Out (Mil) | 28.0 | 77.7 | 35% |
|
| Institutional Ownership | 60.1% | 86.1% | 39% |
|
| Float (Mil) | 16.7 | 52.1 | 26% |
|
| Beta | 0.89 | 0.75 | 53% |
|
| Avg Daily Volume (000s) | 198 | 637 | 44% |
|
| Price Change (52-week) |
(7.8%) | 79.7% | 38% |
|
| Growth | FLGT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (5.2%) | 10.9% | 8% |
|
| Net Income (5yr) | (17.9%) | (1.6%) | 22% |
|
| EPS (5yr) | (17.3%) | 0.3% | 16 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.4%) | (17.9%) | 49% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.650) | ($2.270) | ($1.380) | |
| Month Ago EPS | ($0.360) | ($1.550) | ($1.150) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.360) | ($1.550) | ($1.150) | |
| Year/Year Chg | (38.3%) | 15.2% | (40.1%) | |
| Financials | FLGT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $324 | $1,504 | 36% |
|
| Net Income (TTM) (Mil) | ($84) | $28 | 12% |
|
| EPS (TTM) | ($2.799) | $0.200 | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($84) | $162 | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($62) | $9 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $338 | 26% |
|
| Enterprise Value (Q1) (Mil) | ($92) | $2,416 | 0% |
|
| Valuation | FLGT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.55 | 2.79 | 9% |
|
| P/E | na | 25.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | FLGT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 35.6% | 27.8% | 43% |
|
| Net Margin | (26.0%) | 1.2% | 15% |
|
| ROA | (7.4%) | 2.2% | 27% |
|
| ROE | (8.0%) | 7.2% | 29% |
|
| Liabilities to Assets | 8.6% | 58.6% | 5% |
|
| F-Score | 4 | 5 | 34% |
|
Fulgent Genetics, Inc. did not pass any screens on 8/20/2026.
